Arthur A Levin Avidity Biosciences, Inc. (RNA) insider trading activity

Arthur A Levin is Director of Avidity Biosciences, Inc.. Currently has a direct ownership of 19,650 shares of RNA, which is worth approximately $868,137. The most recent transaction as insider was on Mar 15, 2023, when has been sold 100 shares (Common Stock) at a price of $22.01 per share, resulting in proceeds of $2,201. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 19.7K

0% 3M change

32.5% 12M change

Total Value Held $868,137

ARTHUR A LEVIN Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Mar 15 2023	SELL Open market or private sale	$2,201 $22.01 p/Share	100 Reduced 0.51%	19,330 Common Stock
Mar 15 2023	BUY Exercise of conversion of derivative security	$124 $1.24 p/Share	100 Added 0.51%	19,430 Common Stock
Feb 14 2023	SELL Open market or private sale	$239,300 $23.93 p/Share	10,000 Reduced 34.09%	19,330 Common Stock
Feb 14 2023	BUY Exercise of conversion of derivative security	$12,400 $1.24 p/Share	10,000 Added 25.43%	29,330 Common Stock
Jan 20 2023	BUY Grant, award, or other acquisition	-	18,000 Added 48.22%	19,330 Common Stock
Jan 12 2023	SELL Open market or private sale	$220,000 $22.0 p/Share	10,000 Reduced 88.26%	1,330 Common Stock
Jan 12 2023	BUY Exercise of conversion of derivative security	$12,400 $1.24 p/Share	10,000 Added 46.88%	11,330 Common Stock
Dec 29 2022	SELL Open market or private sale	$880,400 $22.01 p/Share	40,000 Reduced 96.78%	1,330 Common Stock
Dec 29 2022	BUY Exercise of conversion of derivative security	$49,600 $1.24 p/Share	40,000 Added 49.18%	41,330 Common Stock
Aug 16 2022	SELL Open market or private sale	$77,258 $22.08 p/Share	3,499 Reduced 72.46%	1,330 Common Stock
Aug 16 2022	BUY Exercise of conversion of derivative security	$4,339 $1.24 p/Share	3,499 Added 42.01%	4,829 Common Stock
Aug 15 2022	SELL Open market or private sale	$1,382,456 $22.12 p/Share	62,498 Reduced 97.92%	1,330 Common Stock
Aug 15 2022	BUY Exercise of conversion of derivative security	$55,623 $0.89 p/Share	62,498 Added 49.47%	63,828 Common Stock
Aug 12 2022	SELL Open market or private sale	$308,066 $22.0 p/Share	14,003 Reduced 91.33%	1,330 Common Stock
Aug 12 2022	BUY Exercise of conversion of derivative security	$7,422 $0.53 p/Share	14,003 Added 47.73%	15,333 Common Stock
Nov 18 2021	SELL Open market or private sale	$697,250 $27.89 p/Share	25,000 Reduced 94.95%	1,330 Common Stock
Nov 18 2021	BUY Exercise of conversion of derivative security	$22,250 $0.89 p/Share	25,000 Added 48.7%	26,330 Common Stock
Jun 25 2021	SELL Open market or private sale	$573,855 $28.55 p/Share	20,100 Reduced 93.79%	1,330 Common Stock
Jun 25 2021	BUY Exercise of conversion of derivative security	$17,889 $0.89 p/Share	20,100 Added 48.4%	21,430 Common Stock
Jun 24 2021	SELL Open market or private sale	$2,775 $27.75 p/Share	100 Reduced 6.99%	1,330 Common Stock
Jun 24 2021	BUY Exercise of conversion of derivative security	$124 $1.24 p/Share	100 Added 6.54%	1,430 Common Stock
Jun 17 2021	SELL Open market or private sale	$5,550 $27.75 p/Share	200 Reduced 13.07%	1,330 Common Stock
Jun 17 2021	BUY Exercise of conversion of derivative security	$248 $1.24 p/Share	200 Added 11.56%	1,530 Common Stock
Mar 16 2021	SELL Open market or private sale	$128,202 $27.87 p/Share	4,600 Reduced 100.0%	0 Common Stock
Mar 16 2021	BUY Exercise of conversion of derivative security	$4,094 $0.89 p/Share	4,600 Added 50.0%	4,600 Common Stock

Also insider at

STOK

Stoke Therapeutics, Inc. Healthcare

AAL

Arthur A Levin

Director

San Diego, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells RNA shares.

Notify only if

Value

Insider Trading

Get notified when an Avidity Biosciences, Inc. insider buys or sells RNA shares.

Notify only if

Operation

Value

Type

News

Receive news related to Avidity Biosciences, Inc.

Track Activities on RNA

Account